MedPath
HSA Approval

RYKINDO EXTENDED-RELEASE INJECTABLE SUSPENSION 50MG/VIAL

SIN17185P

RYKINDO EXTENDED-RELEASE INJECTABLE SUSPENSION 50MG/VIAL

RYKINDO EXTENDED-RELEASE INJECTABLE SUSPENSION 50MG/VIAL

February 20, 2025

LUYE PHARMA (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantLUYE PHARMA (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SUSPENSION, EXTENDED RELEASE

INTRAMUSCULAR

Medical Information

N05AX08

Manufacturer Information

LUYE PHARMA (SINGAPORE) PTE. LTD.

Shandong Luye Pharmaceutical Co., Ltd.

Shandong Luye Pharmaceutical Co., Ltd. (Diluent)

Active Ingredients

Risperidone

50mg/vial

Risperidone

Documents

Package Inserts

Rykindo PI.pdf

Approved: February 20, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

RYKINDO EXTENDED-RELEASE INJECTABLE SUSPENSION 50MG/VIAL - HSA Approval | MedPath